Stocks
BMY-AZN Merger Denial Puts Pharma M&A Outlook in Focus
A Financial Times report of BMY-AZN merger talks was swiftly denied by Reuters sources, reigniting debate on Big Pharma M&A prospects. Seeking...
#bristol myers squibb 2 articles
Markets
Bristol Myers Squibb: A Value Contender in Pharma
Bristol Myers Squibb (BMY) shows compelling value with a low forward P/E and a 4.2% dividend yield, despite concerns over legacy drug...